China Nifuratel Market Investigation Report 2015
DUBLIN, Sep. 03, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/mklqgt/investigation) has announced the addition of the "Investigation Report on China Nifuratel Market, 2010-2019" report to their offering.
Nifuratel can effectively kill those bacteria, protozoa and molds that lead to vaginal infections without any acute or chronic side effects. Due to its pleiotropic effects, nifuratel can be used for all kinds of vaginitis caused by bacteria, trichomonas and molds infection. Nifuratel, a variety of broad- spectrum antimicrobial agents with two methods of application: oral and external application, was developed by Doppel Farmaceutici. S. r. l. with the trade name of Macmiror/ Macmiror. In 2001, SFDA approved nifuratel made by Doppel Farmaceutici. S. r. l. to be sold in China with such main species as sugarcoated tablets, vaginal tablets and vaginal suppositories under the trade names of Macmiror and Macmiror Complex. Nifuratel develops fast after entering China with annual sales rising from CNY 53.2 thousand in 2005 to CNY 38.03 million in 2014 and CAGR reaching 24.43% and some Chinese enterprises have also started to make generic drugs.
With the fast development of Chinese economy and the improvement of national health insurance system, many kinds of gynecological inflammation drugs, driven by new concepts of treatment, have become affordable to civilians. In general, the gynecological anti- infective market in sample hospitals is dominated by pharmaceutical preparations which operate quickly. On the other hand, Chinese patent medicine made by local enterprises fail to enter the market, instead, they are widely used in mother and child healthcare hospitals, medical institutions based in communities as well as the rural market.
Key Topics Covered:
1 Related Concepts of Nifuratel
2 Market Profile of Nifuratel in China, 2010-2015
3 Survey on Sales Status of Nifuratel in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Nifuratel in China, 2010-2014
5 Survey on Dosage Forms of Nifuratel in China, 2010-2014
6 Reference Price of Nifuratel in Chinese Hospitals in 2014
7 Major Manufacturers of Nifuratel in Chinese Market, 2010-2014
8 Market Outlook of Nifuratel in China, 2015-2019
Companies Mentioned
- Lifecare
- Beijing Laneva Pharmaceutical Co., Ltd
- Yantai Luyin Pharmaceutical Co., Ltd
- Doppel Farmaceutici (Italy)
- Monsanto Italy S.p.A.
For more information visit http://www.researchandmarkets.com/research/mklqgt/investigation
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article